Conjugation of Polycationic Peptides Extends the Efficacy Spectrum of β-Lactam Antibiotics.

Autor: Werner J; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Umstätter F; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Böhmann MB; Department of Pharmaceutical Technology, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69120, Heidelberg, Germany., Müller H; Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, 72076, Tübingen, Germany., Beijer B; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Hertlein T; Institute of Molecular Infection Biology, University of Würzburg, 97080, Würzburg, Germany., Kaschnitz L; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Bram V; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Kleist C; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Klika KD; NMR Spectroscopy Analysis Unit, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Mühlberg E; Department of Pharmaceutical Technology, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69120, Heidelberg, Germany., Braune G; Institute of Molecular Infection Biology, University of Würzburg, 97080, Würzburg, Germany., Wohlfart S; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Gärtner M; Department of Pharmaceutical and Bioorganic Chemistry, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69120, Heidelberg, Germany., Peter S; Medical Microbiology, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, 72076, Tübingen, Germany., Zimmermann S; Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University Hospital, 69120, Heidelberg, Germany., Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Ohlsen K; Institute of Molecular Infection Biology, University of Würzburg, 97080, Würzburg, Germany., Brötz-Oesterhelt H; Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, 72076, Tübingen, Germany., Mier W; Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany., Uhl P; Department of Pharmaceutical Technology, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69120, Heidelberg, Germany.

Publikováno v: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2024 Nov 05, pp. e2411406. Date of Electronic Publication: 2024 Nov 05.

VI. Translation into French of ‘Amynt’ by Ewald Christian von Kleist, c. 14 November 1764

Autor: Ewald Christian von Kleist, Marlies K. Danziger, James Boswell

Publikováno v: The Yale Editions of the Private Papers of James Boswell: Research Edition: Journals, Vol. 1: James Boswell: The Journal of his German and Swiss Travels, 1764: The Journal of his German and Swiss Travels, 1764

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7742f88d4a34037cf7f619aa419bf96e
https://doi.org/10.1093/oseo/instance.00184266

VI. Translation into French of ‘Amynt’ by Ewald Christian von Kleist, c. 14 November 1764

Autor: Boswell, James, Kleist, Ewald Christian

Publikováno v: The Yale Editions of the Private Papers of James Boswell: Research Edition: Journals, Vol. 1: James Boswell: The Journal of his German and Swiss Travels, 1764: VI. Translation into French of ‘Amynt’ by Ewald Christian von Kleist, c. 14 November 1764.

Externí odkaz: http://dx.doi.org/10.1093/oseo/instance.00184266

Improved pharmacokinetics and enhanced efficacy of the vancomycin derivative FU002 using a liposomal nanocarrier.

Autor: Werner J; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany., Umstätter F; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany., Hertlein T; University of Würzburg, Institute for Molecular Infection Biology, Würzburg, Germany., Beijer B; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany., Kleist C; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany., Mühlberg E; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany., Zimmermann S; Heidelberg University Hospital, Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg, Germany., Haberkorn U; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany., Ohlsen K; University of Würzburg, Institute for Molecular Infection Biology, Würzburg, Germany., Fricker G; Heidelberg University, Institute of Pharmacy and Molecular Biotechnology, Heidelberg, Germany., Mier W; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany., Uhl P; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany; Heidelberg University, Institute of Pharmacy and Molecular Biotechnology, Heidelberg, Germany. Electronic address: philipp.uhl@med.uni-heidelberg.de.

Publikováno v: Nanomedicine : nanotechnology, biology, and medicine [Nanomedicine] 2024 Feb; Vol. 56, pp. 102731. Date of Electronic Publication: 2023 Dec 27.

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.

Autor: Schaier M; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany.; TolerogenixX GmbH, Heidelberg, ;Germany., Morath C; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany.; TolerogenixX GmbH, Heidelberg, ;Germany.; German Center for Infection Research, German Center for Infection Research (DZIF), Thematic Translational Unit (TTU)-Infections of the Immunocompromised Host (IICH), Partner Site Heidelberg, Heidelberg, ;Germany., Wang L; TolerogenixX GmbH, Heidelberg, ;Germany.; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, ;Germany., Kleist C; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany.; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, ;Germany., Opelz G; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany., Tran TH; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany., Scherer S; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany., Pham L; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany., Ekpoom N; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany., Süsal C; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany.; Transplant Immunology Research Center of Excellence, Koç University, Istanbul, ;Türkiye., Ponath G; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany.; TolerogenixX GmbH, Heidelberg, ;Germany., Kälble F; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany., Speer C; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany., Benning L; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany., Nusshag C; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany., Mahler CF; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany., Pego da Silva L; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany., Sommerer C; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany.; German Center for Infection Research, German Center for Infection Research (DZIF), Thematic Translational Unit (TTU)-Infections of the Immunocompromised Host (IICH), Partner Site Heidelberg, Heidelberg, ;Germany., Hückelhoven-Krauss A; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, ;Germany., Czock D; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, ;Germany., Mehrabi A; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, ;Germany., Schwab C; Institute of Pathology, Heidelberg University Hospital, Heidelberg, ;Germany., Waldherr R; Institute of Pathology, Heidelberg University Hospital, Heidelberg, ;Germany., Schnitzler P; Center for Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, ;Germany., Merle U; Department of Gastroenterology, Heidelberg University Hospital, Heidelberg, ;Germany., Schwenger V; Department of Nephrology, Klinikum der Landeshauptstadt Stuttgart, Stuttgart, ;Germany., Krautter M; Department of Nephrology, Klinikum der Landeshauptstadt Stuttgart, Stuttgart, ;Germany., Kemmner S; Transplant Center, University Hospital Munich, Ludwig-Maximilians University (LMU), Munich, ;Germany., Fischereder M; Division of Nephrology, Department of Internal Medicine IV, University Hospital Munich, Ludwig-Maximilians-Universität München (LMU), Munich, ;Germany., Stangl M; Department of General, Visceral, and Transplant Surgery, University Hospital Munich, Ludwig-Maximilians-Universität München (LMU), Munich, ;Germany., Hauser IA; Medical Clinic III, Department of Nephrology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, ;Germany., Kälsch AI; Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, ;Germany., Krämer BK; Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, ;Germany., Böhmig GA; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, ;Austria., Müller-Tidow C; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, ;Germany., Reiser J; Department of Medicine, Rush University, Chicago, IL, ;United States., Zeier M; Department of Nephrology, Heidelberg University Hospital, Heidelberg, ;Germany., Schmitt M; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, ;Germany., Terness P; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany., Schmitt A; TolerogenixX GmbH, Heidelberg, ;Germany.; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, ;Germany., Daniel V; Institute of Immunology, Heidelberg University Hospital, Heidelberg, ;Germany.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jul 11; Vol. 14, pp. 1089664. Date of Electronic Publication: 2023 Jul 11 (Print Publication: 2023).